Five things for pharma marketers to know: Friday, April 7, 2017
1. The FDA issued a complete response letter to Merck, rejecting the drugmaker's bid to add results of an outcomes trial to the label of its diabetes drug Januvia. The trial's results had showed that the drug did not raise the risk of heart attack or stroke.
2. Unity Stoakes, a co-founder of Startup Health, a digital health accelerator, said funding was hurt by a lack of clarity from President Trump's healthcare policies in the first three months of the year. (Crain's New York)
3. The FDA approved 23andMe's DTC genetic test, which can assess a person's genetic risk of contracting 10 diseases or conditions, including Alzheimer's disease, Parkinson's disease, celiac disease, and a hereditary blood-clot condition. However, the test does not assess the overall risk of contracting one of the 10 diseases. (WSJ)
4. Mallinckrodt Pharmaceuticals plans to leave PhRMA ahead of a possible change to the lobbying group's bylaws that reportedly would deny membership to companies that don't spend a significant amount of money on R&D. (WSJ)
5. ICYMI: Magna, a research firm operating in the IPG network, forecast that the pharma industry will have “stronger-than-average” ad spend growth in 2017. In a phone interview, the authors attributed the forecast to increased outlays in direct-to-consumer advertising. (Magna Forecast)